FDA Approved Utebzi, the First Oral Carbapenem, for Complicated UTIs
The June 17, 2026 approval of tebipenem lets some kidney-infection patients leave the infusion chair for a pill — if stewardship rules hold the line on use.
Health News
Health News carries guideline revisions, approvals, recalls and advisories, each item naming the issuing body behind it.
Sector news category — verified health events only (FDA, guidelines, major studies)
FDA Approved Hepcludex, Closing the US Gap in Hepatitis D Treatment
The May 22, 2026 approval of bulevirtide brings the entry-blocker used in Europe since 2020 to US adults with chronic hepatitis delta. Who should be tested.
FDA Approved Veppanu for the Mutation That Ends Hormone Therapy's Run
The May 1, 2026 approval of epdegestrant targets ESR1-mutated HR-positive metastatic breast cancer. Why genomic testing at relapse decides who qualifies.
FDA Approved Foundayo: the Oral GLP-1 That Rewrites Obesity Drug Economics
The April 1, 2026 approval of orforglipron brings GLP-1 weight-loss therapy to a daily tablet manufactured at standard scale. Efficacy, side effects, coverage.
FDA Approved Icotyde, Taking the Top Psoriasis Target From Injection to Pill
The March 17, 2026 approval of icotrokinra blocks the IL-23 pathway orally. What patients should weigh on efficacy, monitoring, and coverage.
FDA Approved Bysanti: a New Antipsychotic for Schizophrenia and Bipolar I
The February 20, 2026 approval of milsaperidone adds a fresh side-effect profile to a class dominated by generics. What it means for patients and payers.